13310162040
![雙[三(羥甲基)氨基甲烷],CAS:6976-37-0](http://struc.chem960.com/strucimg/7000/ctzw0nzi34oyob9fnlmhiwee.png)
BioXCell的中和/阻斷抗體受到國內外研究者的普遍熱愛和青睞，在腫瘤、癌癥等方面的研究中廣受好評。BioXCell公司位于美國新罕布什爾州，具有25年以上單克隆抗體和重組蛋白的生產及定制經驗，可提供高純度、低內毒素、無防腐劑、適用于體內臨床前研究的單克隆抗體。
欣博盛生物是Bioxcell一級代理商，Bioxcell國內唯一庫存中心。如需購買Bioxcell公司產品，請聯系我們。
 |
高純度、低內毒素，無防腐劑，適用于體內臨床前研究 |
| 超過二十五年單克隆抗體和重組蛋白生產及定制經驗 | |
| 性價比高，可提供100mg甚至50g的大包裝 | |
| 超過15000篇高質量期刊文獻引用 |
腫瘤癌癥免疫治療應用
●抑制免疫檢查點和其他免疫調節來治療惡性腫瘤是現在利用免疫系統殺死腫瘤細胞的有力途徑。BioXCell提供三種不同克隆號的anti mouse PD-1抗體：RMP1-14、29F.1A12和J43。三種抗體都通過相同的機制發揮作用—它們結合PD-1，并在空間上阻斷PD-1與PD-1配體的結合，從而阻斷PD-1信號傳導。這三種克隆號的抗體都非常適合在小鼠體內模型中阻斷PD-1信號傳導，并有大量文獻支持這一應用。這些抗體之間的差異在于文獻報道中的其他應用、Isotype和來源。
●通過用阻斷PD-L1和它的受體PD-1之間的相互作用的抗體治療，腫瘤生長可以暫時被抑制。
●抗PD-1聯合抗CTLA-4抗體介導的免疫治療對黑色素瘤、腎細胞癌和非小細胞肺癌具有顯著療效。
●通過靶向調節免疫反應的途徑，如RANK途徑，可以將“cold”腫瘤轉化為“hot”腫瘤。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody，研究人員證明了對RANK通路的抑制將“cold”乳腺腫瘤轉化為“hot”腫瘤，變為“hot”的腫瘤可能受益于免疫療法。
腫瘤研究相關的抗體
| 抗體指標 | 應用 | 克隆號 | InVivoMab | InVivoPlus | 同型對照 | 稀釋液 |
| Anti mouse PD-1(CD279) | In vivo blocking of PD-1/PD-L signaling | RMP1-14 | BE0146 | BP0146 | BE0089 | IP0070 |
| In vivo blocking of PD-1/PD-L signaling In vitro PD-1 neutralization IHC-Fr/Immunofluorescence/WB/FC |
29F.1A12 | BE0273 | BP0273 | BE0089 | IP0070 | |
| In vivo blocking of PD-1/PD-L signaling In vitro PD-1 neutralization WB |
J43 | BE0033-2 | BP0033-2 | BE0091 | IP0065 | |
| Anti mouse PD-L1(B7-H1) | In vivo PD-L1 blockade IHC-Fr/Immunofluorescence/WB/FC |
10F.9G2 | BE0101 | BP0101 | BE0090 | IP0065 |
| Anti mouse CTLA-4 (CD152) | In vivo CTLA-4 neutralization WB |
9D9 | BE0164 | BP0164 | BE0086 | IP0070 |
| In vivo CTLA-4 neutralization In vitro CTLA-4 neutralization WB |
9H10 | BE0131 | BP0131 | BE0087 | IP0070 | |
| In vivo CTLA-4 neutralization In vitro CTLA-4 neutralization WB/FC |
UC10-4F10-11 | BE0032 | BP0032 | BE0091 | IP0065 | |
| Anti mouse CD4 | In vivo CD4+ T cell depletion WB/FC |
GK1.5 | BE0003-1 | BP0003-1 | BE0090 | IP0065 |
| Anti mouse CD8α | In vivo CD8+ T cell depletion Immunofluorescence/WB/FC |
53-6.7 | BE0004-1 | BP0004-1 | BE0089 | IP0065 |
| In vivo CD8+ T cell depletion WB |
2.43 | BE0061 | BP0061 | BE0090 | IP0070 | |
| In vivo CD8+ T cell depletion WB |
YTS 169.4 | BE0117 | BP0117 | BE0090 | IP0070 | |
| Anti mouse Ly6G | In vivo neutrophil depletion In vivo MDSC depletion IHC-P/IHC-Fr/IF/FC |
1A8 | BE0075-1 | BP0075-1 | BE0089 | IP0065 |
| Anti mouse Ly6G/Ly6C (Gr-1) | In vivo depletion of Gr-1+ myeloid cells IHC-P/IHC-Fr/FC |
RB6-8C5 | BE0075 | BP0075 | BE0090 | IP0070 |
| Anti mouse IFNγ | In vivo IFN-γ neutralization In vitro IFN-γ neutralization ELISPOT/WB/FC |
XMG1.2 | BE0055 | BP0055 | BE0088 | IPT080 |
| Anti mouse IFNAR-1 | In vivo IFNAR-1 blockade In vitro IFNAR-1 blockade WB |
MAR1-5A3 | BE0241 | BP0241 | BE0083 | IP0070 |
|
Anti-mouse/human/rat/monkey/hamster/ canine/bovine TGF-β |
In vivo TGF-β neutralization In vitro TGF-β neutralization WB |
1D11.16.8 | BE0057 | BP0057 | BE0083 | IP0070 |
| Anti mouse CD28 | In vitro T cell stimulation/activation In vivo CD28 blockade |
37.51 | BE0015-1 | / | BE0087 | IPT060 |
| in vitro T cell stimulation/activation | PV-1 | BE0015-5 | / | BE0091 | IP0070 | |
| Anti mouse CD3ε | In vitro T cell stimulation/activation In vivo T cell depletion Immunofluorescence/WB/FC |
145-2C11 | BE0001-1 | BP0001-1 | BE0091 | IP0070 |
| Anti-human CD3 | In vitro T cell stimulation/activation In vivo T cell depletion in humanized mice Ex vivo T cell inhibition for xenografts FC |
OKT-3 | BE0001-2 | / | BE0085 | IP0070 |
| Anti mouse CD40 | In vivo CD40 activation In vitro B cell stimulation/activation |
FGK4.5/ FGK45 | BE0016-2 | BP0016-2 | BE0089 | IP0070 |
| Anti mouse CD154 (CD40L) | In vivo blocking of CD40/CD40L signaling In vitro blocking of CD40/CD40L signaling WB |
MR-1 | BE0017-1 | BP0017-1 | BE0091 | IP0070 |
| Anti mouse CD25 (IL-2Rα) | In vivo regulatory T cell depletion FC |
PC-61.5.3 | BE0012 | BP0012 | BE0088 | IP0070 |
| Anti mouse IL-4 | In vivo IL-4 neutralization In vitro IL-4 neutralization In vivo IL-4 receptor stimulation (as a complex with IL-4) FC/WB |
11B11 | BE0045 | BP0045 | BE0088 | IP0070 |
| Anti mouse NK1.1 | In vivo NK cell depletion FC |
PK136 | BE0036 | BP0036 | BE0085 | IP0070 |
| Anti mouse CSF1R (CD115) | In vivo macrophage depletion In vitro CSF1R neutralization In vivo monocyte depletion FC/WB |
AFS98 | BE0213 | BP0213 | BE0089 | IP0070 |
| Anti mouse CD25 (IL-2Rα) | In vivo regulatory T cell depletion FC |
PC-61.5.3 | BE0012 | BP0012 | BE0088 | IP0070 |
| anti-mouse OX40 (CD134) | In vivo OX40 activation In vitro OX40 activation WB |
OX-86 | BE0031 | BP0031 | BE0088 | IP0070 |
暢銷同型對照抗體
| 同型對照 | InVivoMab | InVivoPlus |
| 目錄號 | 目錄號 | |
| Rat IgG2a Isotype control, FC | BE0089 | BP0089 |
| Rat IgG2b Isotype control | BE0090 | BP0090 |
| Mouse IgG1 Isotype control | BE0083 | BP0083 |
| Rat IgG1 Isotype control | BE0088 | BP0088 |
| Mouse IgG2a Isotype control | BE0085 | BP0085 |
| Mouse IgG2b Isotype control | BE0086 | BP0086 |
| Polyclonal Armenian Hamster IgG | BE0091 | BP0091 |
InVivoPlus? Vs InVivoMab?系列之間區別
| InVivoMab | InVivoPlus | |
| 純度 | > 95% | > 95% |
| 蛋白完整性 | √ (verified via SDS-PAGE) | √ü(verified via SDS-PAGE) |
| 內毒素濃度 | < 2EU/mg | < 1EU/mg |
| 不含疊氮化物和載體蛋白 | √ | √ |
| 是否適用于體內研究 | √ | √ |
| 是否提供大包裝 | √ | √ |
| 是否經WB, FC或ELISA驗證 | √ | |
| 經驗證蛋白聚集≤ 5% | √ | |
| 是否經過鼠科病原體檢測 | √ | |
| 產品貨號 | BE-開頭 | BP-開頭 |
BioXCell的RecombiMAb系列抗體
BioXCell的RecombiMAb系列抗體是新開發的重組單克隆抗體，具有與其傳統克隆號來源相同的抗原結合可變區，但IgG恒定區已從大鼠或倉鼠IgG變為小鼠或人IgG。這意味著對于小鼠模型或人源化小鼠模型的免疫原性降低。
RecombiMAb單克隆抗體
| 產品名稱 | 宿主 | 亞型 | 貨號 | 同型對照 | 稀釋液 | 應用 |
| Anti-Mouse PD-1 (CD279) (D265A) | Mouse | IgG2a, Κ | CP151 | CP150 | IP0070 | in vivo blocking of PD-1/PD-L signaling |
| Anti-Mouse CTLA-4 (CD152) | Mouse | IgG1, Κ | CP146 | BP0083 | IP0070 | In vivo CTLA-4 neutralization In vitro CTLA-4 neutralization WB |
| Human IgG4 (S228P) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG4, Κ | CP147 | - | - | - |
| Human IgG4 S228P L235E P329G (SPLEPG) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG4 | CP148 | - | - | - |
| Human IgG1 (LALA-PG) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG1 | CP149 | - | - | - |
| Mouse IgG2a (D265A) Isotype Control, Anti-Hen Egg Lysozyme | Mouse | IgG2a | CP150 | - | - | - |
BioXCell的重組融合蛋白
融合蛋白即通過將細胞表面受體的結合域與抗體的Fc部分結合而形成，這樣可以使得配體分子不會結合到內源性受體，從而阻斷受體信號的傳導。蛋白純度大于95%，內毒素水平超低，不含防腐劑、穩定劑和載體蛋白等試劑，專為體內研究而開發。
| 貨號 | 產品名稱 | 貨號 | 產品名稱 | 規格 |
| BE0099 | InVivoMAb recombinant CTLA-4-lg | BP0099 | InVivoPlus recombinant CTLA-4-Ig | 5mg，25mg，50mg，100mg |
| BE0098 | InVivoMAb recombinant Flt-3L-lg | BE0148 | InVivoMAb recombinant Mouse Angiostatin-lg | 5mg，25mg，50mg，100mg |
| BE0149 | InVivoMAb recombinant Mouse Endostatin-lg | - | - | 5mg，25mg，50mg，100mg |
產品示例(圖片)：
